FrancophonIA/ELRC3.0 huggingface dataset:
English: This dose may need to be increased after one or two weeks to up to 45 mg once a day if better blood glucose (sugar) control is needed.
Estonian: Kui vere glükoosisisaldust on vaja paremini reguleerida, võib annust ühe või kahe nädala pärast suurendada 45 mg-ni üks kord ööpäevas.
English: Because Pioglitazone Accord is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Estonian: Et Pioglitazone Accord on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Pioglitazone Accordi bioekvivalentsust võrdlusravimiga Actos.
English: Therefore, the CHMP's view was that, as for Actos, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Actose korral, ületab Pioglitazone Accordi kasulikkus sellega kaasnevad riskid.
English: Other information about Pioglitazone Accord
Estonian: Muu teave Pioglitazone Accordi kohta
English: For more information about treatment with Pioglitazone Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Pioglitazone Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: • in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
Estonian: • koos metformiiniga patsientidel, kelle haigust ei saa üksnes metformiiniga rahuldavalt reguleerida, või koos sulfonüüluurearavimiga (teist liiki diabeediravim) patsientidel, kelle haigust ei saa üksnes sulfonüüluurearavimiga rahuldavalt reguleerida ja kellele metformiin ei sobi;
English: This is a summary of the European public assessment report (EPAR) for Pioglitazone Accord.
Estonian: See on ravimi Pioglitazone Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: • together with both metformin and a sulphonylurea in patients who are not satisfactorily controlled despite treatment with two medicines by mouth;
Estonian: • koos metformiini ja sulfonüüluurearavimiga patsientidel, kelle haigust ei saa nende kahe suukaudse ravimiga rahuldavalt reguleerida;
English: • on its own in patients for whom metformin (another diabetes medicine) is not suitable.
Estonian: • ainsa ravimina patsientidel, kellele metformiin (samuti diabeediravim) ei sobi;
English: Pioglitazone Accord contains the active substance pioglitazone.
Estonian: Pioglitazone Accord sisaldab toimeainena pioglitasooni.
English: How does Pioglitazone Accord work?
Estonian: Kuidas Pioglitazone Accord toimib?
English: How has Pioglitazone Accord been studied?
Estonian: Kuidas Pioglitazone Accordi uuriti?
English: Pioglitazone Accord can only be obtained with a prescription.
Estonian: Pioglitazone Accord on retseptiravim.
English: How is Pioglitazone Accord used?
Estonian: Kuidas Pioglitazone Accordi kasutatakse?
English: What are the benefits and risks of Pioglitazone Accord?
Estonian: Milles seisneb Pioglitazone Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: What measures are being taken to ensure the safe and effective use of Opsumit?
Estonian: Mis meetmed võetakse, et tagada Opsumiti ohutu ja efektiivne kasutamine?
English: Opsumit received a marketing authorisation valid throughout the EU on 20 December 2013.
Estonian: Opsumit on saanud müügiloa, mis kehtib kogu ELis, 20. detsembril 2013.
English: Women should also not become pregnant for one month after stopping treatment.
Estonian: Samuti ei tohi naised ühe kuu jooksul alates ravi lõpetamisest rasestuda.
English: Opsumit (macitentan)
Estonian: Opsumit (matsitentaan)
English: The European Medicines Agency decided that Opsumit's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Opsumiti kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The medicine is available as 10 mg tablets and taken at a dose of one tablet every day.
Estonian: Ravimit turustatakse 10 mg tablettidena ja seda võetakse üks tablett ööpäevas.
English: As for all medicines, data on the use of Opsumit are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Opsumiti kasutamise kohta pidevat järelevalvet.
English: What is Opsumit and what is it used for?
Estonian: Mis on Opsumit ja milleks seda kasutatakse?
English: Other information about Opsumit
Estonian: Muu teave Opsumiti kohta
English: Side effects reported with Opsumit are carefully evaluated and any necessary action taken to protect patients.
Estonian: Opsumiti kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Further information on Opsumit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Lisateave Opsumiti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports..
English: Further information on the orphan designation can be found on the European Medicines Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Lisateave harvikravimiks nimetatud ravimi kohta on leitav Euroopa Ravimiameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: Most side effects are mild to moderate in severity.
Estonian: Enamik kõrvalnähte on raskusastmelt kerged kuni mõõdukad.
English: In animal studies, Opsumit was shown to have an adverse effect on the development of embryos.
Estonian: Loomkatsetes täheldati Opsumiti kahjulikku toimet embrüo arengule.
English: These are part of a natural mechanism in the body that can cause arteries to narrow.
Estonian: Need retseptorid on osa organismi looduslikust mehhanismist, mis põhjustab arterite ahenemist.
English: For more information about using Opsumit, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Opsumiti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: The company that markets Opsumit will send educational material to patients and healthcare professionals with information on the precautions to be taken when using Opsumit.
Estonian: Opsumiti turustaja edastab patsientidele ja tervishoiutöötajatele teabematerjalid teabega ettevaatusmeetmetest, mida tuleb võtta Opsumiti kasutamisel.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Opsumit have also been included in the summary of product characteristics and the package leaflet.
Estonian: Opsumiti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The most common side effects with Opsumit (which may affect more than 1 in 10 people) include nasopharyngitis (inflammation of the nose and throat), anaemia (low red blood cell counts) and headache.
Estonian: Opsumiti kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on nasofarüngiit (nina-neelupõletik), aneemia (erütrotsüütide vähesus) ja peavalu.
English: What are the risks associated with Opsumit?
Estonian: Mis riskid Opsumitiga kaasnevad?
English: In a main study involving 742 patients, Opsumit has been shown to reduce the risk of PAH-related illness, particularly the worsening of PAH symptoms.
Estonian: 742 patsiendiga põhiuuringus tõendati, et Opsumit vähendas kopsu arteriaalse hüpertensiooniga seotud haigestumise riski, eelkõige kopsu arteriaalse hüpertensiooni sümptomite süvenemise riski.
English: Opsumit contains the active substance macitentan.
Estonian: Opsumit sisaldab toimeainena matsitentaani.
English: The class reflects the seriousness of the disease: patients with class II PAH have slight limitation of physical activity and those with class III disease have marked limitation of physical activity.
Estonian: Funktsionaalne klass kajastab haiguse raskusastet: II klassi korral on patsientide füüsiline aktiivsus veidi piiratud ning III klassi korral oluliselt piiratud.
English: How is Opsumit used?
Estonian: Kuidas Opsumitit kasutatakse?
English: Opsumit is used for adults whose PAH is classified as WHO functional class II to class III.
Estonian: Opsumitit kasutatakse täiskasvanutel, kellel kopsu arteriaalne hüpertensioon on liigitatud WHO II või III funktsionaalsesse klassi kuuluvaks.
English: Patients' reminder cards will include a warning that the medicine must never be used in pregnant women and that women who could become pregnant must be using reliable contraception and should undergo monthly pregnancy tests.
Estonian: Patsientide meelespeasse lisatakse hoiatus, et ravimit ei tohi mingil juhul kasutada rasedad ning et rasestumisvõimelised naised peavad kasutama usaldusväärseid rasestumisvastaseid vahendeid ja tegema igal kuul rasedustesti.
English: PAH is a condition in which there is abnormally high blood pressure in the arteries of the lungs, causing symptoms such as breathlessness and fatigue.
Estonian: Kopsu arteriaalne hüpertensioon on haigusseisund, mille korral vererõhk kopsuarterites on ebanormaalselt kõrge, mis põhjustab selliseid sümptomeid nagu hingeldus ja väsimus.
English: Opsumit is a medicine used for the long-term treatment of pulmonary arterial hypertension (PAH).
Estonian: Opsumit on ravim, mida kasutatakse kopsu arteriaalse hüpertensiooni pikaajaliseks raviks.
English: Opsumit must therefore not be used in pregnant or breastfeeding women or in women who could become pregnant and who are not using reliable contraception.
Estonian: Seetõttu ei tohi Opsumitit kasutada rasedad, imetavad ega rasestumisvõimelised naised, kes ei kasuta usaldusväärseid rasestumisvastaseid vahendeid.
English: However, as animal studies showed an adverse effect on the development of embryos, Opsumit must never be used in pregnant women or women who could become pregnant and are not using reliable contraception.
Estonian: Kuna aga loomkatsetes täheldati kahjulikku toimet embrüo arengule, ei tohi Opsumitit mingil juhul kasutada rasedad ning rasestumisvõimelised naised, kes ei kasuta usaldusväärseid rasestumisvastaseid vahendeid.
English: For the full list of side effects reported with Opsumit, see the package leaflet.
Estonian: Opsumiti kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What benefits of Opsumit have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Opsumiti kasulikkus?
English: Around 37% of patients taking placebo had a worsening of their PAH symptoms compared with 24% of those who took Opsumit 10 mg.
Estonian: Patsiente, kellel süvenesid kopsu arteriaalse hüpertensiooni sümptomid, oli platseebot kasutanud patsientidest ligikaudu 37% ja Opsumitit annuses 10 mg kasutanud patsientidest 24%.
English: Because more pressure is needed to force blood through the narrowed artery, this leads to high blood pressure in the lungs.
Estonian: Vere pumpamiseks läbi ahenenud arteri on vaja suuremat rõhku ja seepärast põhjustab see kopsudes kõrget vererõhku.
English: An overview of Opsumit and why it is authorised in the EU
Estonian: Ülevaade ravimist Opsumit ja ELis müügiloa väljastamise põhjendus
English: The active substance in Opsumit, macitentan, works by blocking endothelin receptors.
Estonian: Opsumiti toimeaine matsitentaan blokeerib endoteliini retseptorid.
English: It must also not be used in patients with severe reduction in liver function or high levels of liver enzymes in the blood.
Estonian: Opsumitit ei tohi kasutada ka patsiendid, kellel on raske maksakahjustus või kelle vere maksaensüümide sisaldus on suur.
English: In patients with PAH, this mechanism is overactive and, by blocking these receptors, macitentan helps widen the arteries in the lungs and thereby bring down the blood pressure.
Estonian: Blokeerides need retseptorid, aitab matsitentaan kopsuartereid laiendada ja seeläbi vererõhku alandada.
English: Opsumit has been shown to be effective in reducing illness or deaths due to PAH and the side effects reported are similar to those reported with other medicines of its class and are considered to be manageable.
Estonian: Teatatud kõrvalnähud sarnanevad teiste samasse ravimiklassi kuuluvate ravimite kõrvalnähtudega ning neid peetakse hallatavaks.
English: How does Opsumit work?
Estonian: Kuidas Opsumit toimib?
English: PAH is ‘rare', and Opsumit was designated an ‘orphan medicine' (a medicine used in rare diseases) for PAH on 27 September 2011.
Estonian: Kopsu arteriaalne hüpertensioon esineb harva ja Opsumit nimetati kopsu arteriaalse hüpertensiooni harvikravimiks 27. septembril 2011.
English: Patients in the study received either Opsumit or placebo (a dummy treatment) in addition to other PAH treatments for an average of 2 years.
Estonian: Uuringus osalenud patsiendid kasutasid keskmiselt 2 aastat muude kopsu arteriaalse hüpertensiooni raviskeemidele lisaks kas Opsumitit või platseebot (näiv ravim).
English: In PAH there is severe narrowing of the arteries of the lungs.
Estonian: Kopsu arteriaalse hüpertensiooni korral on kopsuarterid tugevalt ahenenud.
English: Opsumit can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in treating PAH.
Estonian: Ravi peab alustama ja jälgima kopsu arteriaalse hüpertensiooni ravis kogenud arst.
English: Opsumit can be used alone or in combination with other PAH medicines; for further information, see the package leaflet.
Estonian: Opsumitit saab kasutada kas ainuravimina või kombinatsioonis muude kopsu arteriaalse hüpertensiooni ravimitega.
English: Why is Opsumit authorised in the EU?
Estonian: ELis Opsumitile väljastatud müügiloa põhjendus
English: The European Commission granted a marketing authorisation valid throughout the European Union for Purevax RCPCh on 23 February 2005.
Estonian: Euroopa Komisjon andis vaktsiini Purevax RCPCh müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 23. veebruaril 2005.
English: The cat should be revaccinated for all components one year after the first vaccination course, then every year for chlamydiosis, and every three years for rhinotracheitis, calicivirosis and panleucopenia.
Estonian: Kass tuleb revaktsineerida kõikide komponentide vastu üks aasta pärast esmast vaktsineerimist ja seejärel igal aastal klamüdioosi vastu ning iga kolme aasta tagant rinotrahheiidi, kalitsiviroosi ja panleukopeenia vastu.
English: It also helps to reduce viral excretion in case of calicivirus infection for one year after vaccination.
Estonian: Kalitsiviirusnakkuse korral aitab see vältida ka viiruse eritumist ühe aasta vältel pärast vaktsineerimist.
English: When a cat is given the vaccine, the immune system recognises the weakened or killed viruses and the weakened bacteria as ‘foreign' and makes antibodies against them.
Estonian: Kui kassile antakse vaktsiini, peab looma immuunsüsteem nõrgestatud või hävitatud viirusi ja nõrgestatud baktereid võõraks ja tekitab nende vastu antikehi.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RCPCh exceed the risks for the approved indications and recommended that Purevax RCPCh be given a marketing authorisation.
Estonian: Veterinaarravimite komitee järeldas, et heakskiidetud näidustustel on vaktsiini Purevax RCPCh kasulikkus suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini Purevax RCPCh müügiloa.
English: Purevax RCPCh is used to vaccinate cats from the age of 8 weeks against the following diseases:
Estonian: Vaktsiini Purevax RCPCh kasutatakse vähemalt 8 nädala vanuste kasside vaktsineerimiseks järgmiste haiguste vastu:
English: When exposed to any of these viruses later in life, the cat will either not become infected or have a much less serious infection.
Estonian: Nende viiruste või bakteritega hiljem elu jooksul kokku puutudes kass ei nakatu või on nakkus märksa kergem.
English: The main measure of effectiveness was the level of antibodies in the blood against the viruses and bacteria in the vaccine.
Estonian: Efektiivsuse põhinäitaja oli vaktsiinis sisalduvate viiruste ja bakterite vastaste antikehade sisaldus veres.
English: The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Estonian: Ravimi kasulikkuse ja riski tasakaal on käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu kokkuvõttes.
English: In the field, the studies of Purevax RCPCh looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination.
Estonian: Vaktsiini Purevax RCPCh väliuuringutes vaadeldi esmast vaktsineerimisskeemi (2 süsti 3-4 nädalase vahega) ja revaktsineerimisskeemi.
English: The effectiveness of Purevax RCPCh has been studied in several trials in laboratory conditions where cats were vaccinated and infected with herpesvirus, calicivirus, C. felis or parvovirus.
Estonian: Vaktsiini Purevax RCPCh efektiivsust uuriti mitmes laborikatses, milles kasse vaktsineeriti ning nakatati herpesviiruse, kalitsiviiruse, C. felis'e või parvoviirusega.
English: In laboratory conditions Purevax RCPCh was demonstrated to provide protection against the diseases listed above.
Estonian: Laboritingimustes tõendati vaktsiini Purevax RCPCh efektiivsust kasside kaitsmisel eespool nimetatud haiguste eest.
English: Purevax RCPCh should not be used in pregnant cats.
Estonian: Vaktsiini Purevax RCPCh ei tohi kasutada tiinetel kassidel.
English: Purevax RCPCh contains small amounts of weakened or killed viruses and bacteria that cause feline rhinotracheitis, calicivirosis, chlamydiosis and panleucopenia.
Estonian: Purevax RCPCh sisaldab väikeses koguses nõrgestatud või hävitatud viirusi ja baktereid, mis põhjustavad kasside rinotrahheiiti, kalitsiviroosi, klamüdioosi ja panleukopeeniat.
English: If self-injection does occur in these people, tell the doctor that self-injection with a living chlamydial vaccine has occurred.
Estonian: Juhusliku enesesüstimise korral peavad need inimesed arstile teatama, et on süstinud endale klamüüdia elusvaktsiini.
English: Purevax RCPCh is a veterinary vaccine that contains:
Estonian: Purevax RCPCh on veterinaarvaktsiin, mis sisaldab järgmisi toimeaineid:
English: Purevax RCPCh is a vaccine.
Estonian: Purevax RCPCh on vaktsiin.
English: What is Purevax RCPCh?
Estonian: Mis on Purevax RCPCh?
English: For a full list of the side-effects reported with Purevax RCPCh, see the package leaflet.
Estonian: Vaktsiini Purevax RCPCh kohta teatatud kõrvaltoimete täielik loetelu on pakendi infolehel.
English: Other information about Purevax RCPCh:
Estonian: Muu teave vaktsiini Purevax RCPCh kohta
English: Why has Purevax RCPCh been approved?
Estonian: Miks Purevax RCPCh heaks kiideti?
English: How does Purevax RCPCh work?
Estonian: Kuidas Purevax RCPCh toimib?
English: Feline viral rhinotracheitis, feline chlamydiosis, feline panleucopenia (live attenuated) and feline calicivirosis (inactivated) vaccine
Estonian: Purevax RCPCh kasside viirusliku rinotrahheiidi, kasside klamüdioosi, kasside panleukopeenia (nõrgestatud elus-) ja kasside kalitsiviroosi (inaktiveeritud) vaktsiin
English: Purevax RCPCh is available as a lyophilisate (freeze-dried pellet) and solvent that are made up into a suspension for injection.
Estonian: Vaktsiini Purevax RCPCh turustatakse süstesuspensiooni lüofilisaadi (külmkuivatatud graanulid) ja lahustina.
English: How has Purevax RCPCh been studied?
Estonian: Kuidas vaktsiini Purevax RCPCh uuriti?
English: What is the risk associated with Purevax RCPCh?
Estonian: Millised riskid vaktsiiniga Purevax RCPCh kaasnevad?
English: What is Purevax RCPCh used for?
Estonian: Milleks vaktsiini Purevax RCPCh kasutatakse?
English: What benefit has Purevax RCPCh shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini Purevax RCPCh kasulikkus?
English: A further study was carried out in 15 female patients.
Estonian: Viidi läbi täiendav uuring 15 naissoost patsiendiga.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Replagal on 3 August 2001.
Estonian: Euroopa Komisjon andis Replagali müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 3. augustil 2001.
English: The full EPAR for Replagal can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Replagali kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: These include chills, headache, nausea, pyrexia (fever), pain and discomfort, flushing and fatigue (tiredness), and are rarely severe.
Estonian: Need on külmavärinad, peavalu, iiveldus, palavik, valu ja ebamugavustunne, õhetus ja väsimus ning need on harva rasked.
English: Other information about Replagal
Estonian: Muu teave Replagali kohta
English: Replagal is given once every 2 weeks as an infusion of 0.2 mg per kilogram body weight over 40 minutes.
Estonian: Replagali manustatakse iga kahe nädala tagant 40 minutit kestva infusioonina annuses 0,2 mg kehakaalu kg kohta.
English: As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 20 July 2015.
Estonian: Et ettevõte esitas vajaliku lisateabe, tühistati müügiloa erandkorras väljastatus 20. juulil 2015.
English: Replagal has also been evaluated in additional studies involving 38 children aged 7 years or above.
Estonian: Replagali hinnati veel lisauuringutes, milles osales 38 vähemalt 7aastast last.
English: People with Fabry disease may have a wide range of signs and symptoms, including severe conditions such as kidney failure, heart problems, and stroke.
Estonian: Fabry tõvega isikutel võib esineda mitmesuguseid nähte ja sümptomeid, sealhulgas raskeid seisundeid, näiteks neerupuudulikkust, südameprobleeme ja insulti.
English: Replagal reduced left ventricle mass by an average of 11.5 g while patients receiving placebo had an increase in left ventricular mass of 21.8 g. The effects in female patients were comparable to those in male patients and weekly dosing had no advantage over standard doses.
Estonian: Replagal vähendas vasaku vatsakese massi keskmiselt 11,5 g, samas kui platseebot saanud patsientide vasaku vatsakese mass suurenes 21,8 g. Toime naispatsientidel oli võrreldav meespatsientide tulemustega ning ravimi iganädalane manustamine ei näidanud eelist võrreldes standardrežiimiga.
English: Replagal agalsidase alfa
Estonian: Replagal alfa-agalsidaas
English: The most common side effects with Replagal (seen in more than 1 patient in 10) are infusionassociated reactions.
Estonian: Replagali kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on tingitud infusioonist.
English: Replagal was originally authorised under ‘exceptional circumstances', because as the disease is rare, limited information was available at the time of approval.
Estonian: Esialgu kiideti Replagal heaks erandkorras, sest haigus esineb harva ja ravimi heakskiitmise ajal ei olnud piisavalt teavet.
English: For more information about treatment with Replagal, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Replagaliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The CHMP decided that Replagal's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Replagali kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Children who received Replagal had no unexpected increase in heart mass, and the levels of Gb3 in their blood were reduced.
Estonian: Replagaliga ravitud lastel ei täheldatud südame massi ootamatut suurenemist ning globotriaosüülkeramiidi sisaldus nende veres oli langenud.